{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:57:12Z","timestamp":1790315832106,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ncl.2018.01.006","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T22:14:50Z","timestamp":1523484890000},"page":"339-353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Measuring Clinical Treatment Response in Myasthenia Gravis"],"prefix":"10.1016","volume":"36","author":[{"given":"Carolina","family":"Barnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Herbelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen M.","family":"Dimachkie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Barohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ncl.2018.01.006_bib1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/ptj\/86.5.726","article-title":"Toward a common language for function, disability, and health","volume":"86","author":"Jette","year":"2006","journal-title":"Phys Ther"},{"key":"10.1016\/j.ncl.2018.01.006_bib2","series-title":"International classification of functioning, disability and health (ICF)","author":"World Health Organization","year":"2002"},{"key":"10.1016\/j.ncl.2018.01.006_bib3","first-page":"889","article-title":"Measuring disease-specific quality of life in clinical trials","volume":"134","author":"Guyatt","year":"1986","journal-title":"Can Med Assoc J"},{"issue":"1","key":"10.1016\/j.ncl.2018.01.006_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0021-9681(85)90005-0","article-title":"A\u00a0methodological framework for assessing health indices","volume":"38","author":"Kirshner","year":"1985","journal-title":"J\u00a0Chronic Dis"},{"issue":"2","key":"10.1016\/j.ncl.2018.01.006_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/erp.11.9","article-title":"A\u00a0point of minimal important difference (MID): a critique of terminology and methods","volume":"11","author":"King","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ncl.2018.01.006_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-4-79","article-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance","volume":"4","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.ncl.2018.01.006_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2288-10-22","article-title":"The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content","volume":"10","author":"Mokkink","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ncl.2018.01.006_bib8","series-title":"Measurement in medicine","author":"De Vet","year":"2011"},{"issue":"5","key":"10.1016\/j.ncl.2018.01.006_bib9","doi-asserted-by":"crossref","first-page":"e98089","DOI":"10.1371\/journal.pone.0098089","article-title":"A\u00a0conceptual framework for evaluating impairments in myasthenia gravis","volume":"9","author":"Barnett","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ncl.2018.01.006_bib10","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ncl.2018.01.006_bib11","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/mus.21185","article-title":"Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve"},{"issue":"9","key":"10.1016\/j.ncl.2018.01.006_bib12","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1212\/WNL.0000000000002971","article-title":"Development and validation of the myasthenia gravis impairment index","volume":"87","author":"Barnett","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2018.01.006_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/archinte.1958.00260190074008","article-title":"Studies in myasthenia gravis; review of two hundred eighty-two cases at the Mount Sinai Hospital, New York City","volume":"102","author":"Osserman","year":"1958","journal-title":"AMA Arch Intern Med"},{"issue":"1","key":"10.1016\/j.ncl.2018.01.006_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2018.01.006_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1749-6632.2012.06771.x","article-title":"Patient registries: useful tools for clinical research in myasthenia gravis","volume":"1274","author":"Baggi","year":"2012","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"10.1016\/j.ncl.2018.01.006_bib16","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1212\/WNL.33.10.1316","article-title":"Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity","volume":"33","author":"Besinger","year":"1983","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ncl.2018.01.006_bib17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ncl.2018.01.006_bib18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.ncl.2018.01.006_bib19","first-page":"286","article-title":"Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis","volume":"247","author":"Sharshar","year":"2000","journal-title":"J\u00a0Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2018.01.006_bib20","first-page":"301","article-title":"Psychometric properties of the quantitative myasthenia gravis score and the myasthenia gravis composite scale","volume":"2","author":"Barnett","year":"2015","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.ncl.2018.01.006_bib21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1196\/annals.1254.057","article-title":"A\u00a0simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score","volume":"998","author":"Sanders","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.ncl.2018.01.006_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/CND.0b013e31824619d5","article-title":"The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers","volume":"13","author":"Barnett","year":"2012","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"issue":"11","key":"10.1016\/j.ncl.2018.01.006_bib23","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1212\/01.WNL.0000163988.28892.79","article-title":"Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity","volume":"64","author":"Bedlack","year":"2005","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ncl.2018.01.006_bib24","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2018.01.006_bib25","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/mus.23988","article-title":"Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial","volume":"49","author":"Katzberg","year":"2014","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.ncl.2018.01.006_bib26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.nmd.2013.02.008","article-title":"Performance of individual items of the quantitative myasthenia gravis score","volume":"23","author":"Barnett","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"15","key":"10.1016\/j.ncl.2018.01.006_bib27","first-page":"939","article-title":"Long-term effects of plasma exchange in myasthenia. Results of a randomized study","volume":"12","author":"Gajdos","year":"1983","journal-title":"Presse Med"},{"issue":"6","key":"10.1016\/j.ncl.2018.01.006_bib28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2018.01.006_bib29","first-page":"449","article-title":"Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis","volume":"235","author":"Mantegazza","year":"1988","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2018.01.006_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.24911","article-title":"Validation of the Besta Neurological Institute Rating Scale for Myasthenia Gravis","volume":"53","author":"Antozzi","year":"2015","journal-title":"Muscle Nerve"},{"issue":"19","key":"10.1016\/j.ncl.2018.01.006_bib31","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1212\/WNL.0b013e3181dd43bf","article-title":"Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7","volume":"74","author":"Lashley","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2018.01.006_bib32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mus.10224","article-title":"Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis","volume":"26","author":"Wolfe","year":"2002","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.ncl.2018.01.006_bib33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG-ADL: still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle Nerve"},{"issue":"18","key":"10.1016\/j.ncl.2018.01.006_bib34","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2018.01.006_bib35","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/mus.21053","article-title":"Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.ncl.2018.01.006_bib36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ncl.2018.01.006_bib37","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2018.01.006_bib38","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/mus.21142","article-title":"Comparison of outcome measures from a trial of Mycophenolate mofetil in myasthenia gravis","volume":"38","author":"Wolfe","year":"2008","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.ncl.2018.01.006_bib39","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A\u00a0trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.006_bib40","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.ncl.2018.01.006_bib41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mus.21880","article-title":"The oculobulbar facial respiratory score is a tool to assess bulbar function in myasthenia gravis patients","volume":"43","author":"Farrugia","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.006_bib42","series-title":"SF-36 health survey","author":"Ware","year":"1993"},{"issue":"5","key":"10.1016\/j.ncl.2018.01.006_bib43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-SD: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"issue":"3","key":"10.1016\/j.ncl.2018.01.006_bib44","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11136-014-0790-9","article-title":"Creating meaningful cut-scores for Neuro-QOL measures of fatigue, physical functioning, and sleep disturbance using standard setting with patients and providers","volume":"24","author":"Cook","year":"2014","journal-title":"Qual Life Res"},{"issue":"23","key":"10.1016\/j.ncl.2018.01.006_bib45","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1212\/WNL.0000000000004676","article-title":"Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency","volume":"89","author":"Barnett","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ncl.2018.01.006_bib46","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/00003246-199803000-00037","article-title":"Frequency and methodologic rigor of quality-of-life assessments in the critical care literature","volume":"26","author":"Heyland","year":"1998","journal-title":"Crit Care Med"},{"issue":"7","key":"10.1016\/j.ncl.2018.01.006_bib47","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/ene.12703","article-title":"Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry","volume":"22","author":"Ramos-Fransi","year":"2015","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2018.01.006_bib48","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3109\/09638288.2013.804591","article-title":"Development of the MG-DIS: an ICF-based disability assessment instrument for myasthenia gravis","volume":"36","author":"Raggi","year":"2014","journal-title":"Disabil Rehabil"},{"issue":"24","key":"10.1016\/j.ncl.2018.01.006_bib49","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.3109\/09638280902893634","article-title":"Identification of international classification of functioning, disability and health relevant categories to describe functioning and disability of patients with myasthenia gravis","volume":"31","author":"Leonardi","year":"2009","journal-title":"Disabil Rehabil"},{"issue":"5","key":"10.1016\/j.ncl.2018.01.006_bib50","first-page":"871","article-title":"Validation of the MG-DIS: a disability assessment for myasthenia gravis","volume":"263","author":"Raggi","year":"2016","journal-title":"J\u00a0Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2018.01.006_bib51","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mus.21016","article-title":"Disease-specific measure of quality of life for myasthenia gravis","volume":"38","author":"Mullins","year":"2008","journal-title":"Muscle Nerve"},{"issue":"23","key":"10.1016\/j.ncl.2018.01.006_bib52","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2018.01.006_bib53","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/jnnp-2011-301449","article-title":"Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis","volume":"84","author":"Barnett","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2018.01.006_bib54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.21883","article-title":"The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis","volume":"43","author":"Burns","year":"2011","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.ncl.2018.01.006_bib55","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.23398","article-title":"The MG-QOL15 Japanese version: validation and associations with clinical factors","volume":"46","author":"Masuda","year":"2012","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.ncl.2018.01.006_bib56","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/mus.25381","article-title":"Translation, cross-cultural adaptation, and validation of the French version of the 15-item myasthenia gravis quality of life scale","volume":"55","author":"Birnbaum","year":"2017","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.ncl.2018.01.006_bib57","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/mus.25198","article-title":"An international clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.ncl.2018.01.006_bib58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A\u00a0randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ncl.2018.01.006_bib59","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2018.01.006_bib60","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mus.20908","article-title":"Surrogate therapeutic outcome measures in patients with myasthenia gravis","volume":"37","author":"Zinman","year":"2008","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.ncl.2018.01.006_bib61","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.ncl.2018.01.006_bib62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/ALN.0000000000001159","article-title":"How much better is good enough? Patient-reported outcomes, minimal clinically important differences, and patient acceptable symptom states in perioperative research","volume":"125","author":"Wijeysundera","year":"2016","journal-title":"Anesthesiology"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861918300069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861918300069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T15:20:49Z","timestamp":1604157649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861918300069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0733861918300069"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2018.01.006","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measuring Clinical Treatment Response in Myasthenia Gravis","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2018.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}